Oura is reportedly eyeing a September IPO that could value it

Back Oura, the smart ring maker, with offices in San Francisco and Finland, is reportedly planning to raise up to $3 billion as soon as next month in a U.S. IPO that values the more than 900-person company at [spits out coffee] north of $16 billion , according to Bloomberg.

The outlet adds that investors are expected to sell a major chunk of stock in the offering.

The wearables space has gotten crowded fast. Samsung launched its own ring, the Galaxy Ring, two years ago. But Oura’s most direct rival may be the fitness band maker Whoop, which has undergone its own reinvention.

For related coverage, explore our detailed analysis on Technology and Digital Systems.

Key Analysis and Detailed Timeline

Once a performance tool for elite athletes and young men, Whoop has spent the past year courting a much broader audience, layering in hormone tracking and blood-panel testing for perimenopause and thyroid health. The move drove its own valuation up to $10 billion back in March.

Oura has followed a similar path, evolving from its starting niche of biohacking CEOs into a more mainstream sleep-and-recovery brand.

Read More: Michael Polansky is training an AI model on skin that’s still alive

Oura confirmed in May that it had filed confidentially for an IPO. The company has stated that it generated $500 million in revenue in 2024, roughly $1 billion in 2025, and that it expected to generate close to $2 billion in revenue in 2026, though we’ll learn much more once its S-1 filing becomes publicly available.

Not all of Oura’s recent attention has been positive. A proposed class action legal action filed last week in San Francisco is accusing Oura of misleading consumers about the accuracy of its sleep tracking features.

Among other complaints in the filing, Oura is accused of not just claiming “to measure a heartbeat or a temperature, but the exact stage of sleep the wearer is in—which in reality requires electrodes in the scalp and sensors on the eyes, as only a hospital or other clinical setting can do.” In a statement to TechCrunch sent over the weekend, a spokesperson pushed back against claims in that suit, saying the company plans to “defend against them in the appropriate legal forum” and that “[w]hile Oura Ring is not a medical device or a substitute for a clinical sleep study, Oura’s sleep staging has been validated and compared favorably in multiple studies against polysomnography, the gold standard.” The statement continued on to say that “[m]ultiple third-party, independent studies support our claims of accuracy and we have transparently reported on the mechanisms and measures that inform Oura’s sleep staging.” When you purchase through links in our articles, we may earn a small commission .

Broader Impact and Sector Outlook

This doesn’t affect our editorial independence. Editor in Chief & General Manager In less than 48 hours, your chance to save up to $300 on your tickets will end!

Two years after launch, Walmart’s Flipkart is closing in on India’s quick-commerce leaders Jagmeet Singh Inherent, founded Michael Polansky is training an AI model on skin that’s still alive Connie Loizos How AI accounting startup Rillet raised $100M and became a unicorn in 48 hours Dominic-Madori Davis Tesla’s solar roof is dead — here’s what went wrong Tim De Chant Oura faces legal action accusing it of misleading consumers about sleep-tracking accuracy Aisha Malik Home batteries are suddenly cheap and everywhere.

Here’s why. Tim De Chant